TabasIWilliamsKJBorénJ. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation2007; 116: 1832–1844.
2.
ChapmanMJGinsbergHNAmarencoP. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J2011; 32: 1345–1361.
3.
NordestgaardBGChapmanMJRayK. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J2010; 31: 2844–2853.
4.
CamposHBlijlevensEMcNamaraJR. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb1992; 12: 1410–1419.
5.
GinsbergHNMacCallumPR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr2009; 4: 113–119.
6.
SnidermanADSt-PierreACCantinB. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol2003; 91: 1173–1177.
7.
WalldiusGJungnerIHolmeI. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet2001; 358: 2026–2033.
8.
McQueenMJHawkenSWangX. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. Lancet2008; 372: 224–233.
9.
Sierra-JohnsonJFisherRMRomero-CorralA. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: Findings from a multi-ethnic US population. Eur Heart J2009; 30: 710–717.
10.
SnidermanADWilliamsKContoisJH. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes2011; 4: 337–345.
11.
Pencina MJ, D’Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future CHD in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol. 2015; 22: 1321–1327.
12.
Di AngelantonioEGaoPPennellsL. Emerging Risk Factors Collaboration: Lipid-related markers and cardiovascular disease prediction. JAMA2012; 307: 2499–2506.
13.
NdumeleCEMatsushitaKAstorB. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: The ARIC study. Eur J Prev Cardiol2014; 21: 866–875.
14.
OtvosJDMoraSShalaurovaI. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol2011; 5: 105–113.
15.
MoraSBuringJERidkerPM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation2014; 129: 553–561.
16.
ColeTGContoisJHCsakoG. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem2013; 59: 752–770.
17.
KoskinenJMagnussenCGWürtzP. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: The Cardiovascular Risk in Young Finns study. Eur J Prev Cardiol2012; 19: 1296–1303.
18.
CatapanoALReinerZDe BackerG. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis2011; 217: 3–46.
19.
GoffDCJrLloyd-JonesDMBennettG. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014; 129(25 Suppl. 2): S49–S73.
20.
ThanassoulisGWilliamsKYeK. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: A meta-analysis of randomized trials. J Am Heart Assoc2014; 3: e000759–e000759.
21.
BrunzellJDDavidsonMFurbergCD. Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol2008; 51: 1512–1524.
22.
Charlton-MenysVBetteridgeDJColhounH. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem2009; 55: 473–480.
23.
American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care2014; 37(Suppl. 1): S14–S80.
24.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl. 2): S1–S45.
25.
RayKKKasteleinJJBoekholdtSM. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J2014; 35: 960–968.
26.
Müller-Wieland D, Assmann G, Carmena R, et al. Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk. Eur J Prev Cardiol. Epub ahead of print 16 January 2015. pii: 2047487314567001.
